Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
Tuberc Respir Dis. 2004 Jul;57(1):32-36. Korean. Original Article. https://doi.org/10.4046/trd.2004.57.1.32
Chung JH , Choi JE , Park MS , Hwang SY , Moon JW , Kim YS , Chang J , Kim JH , Kim SK , Kim SK .
Department of Internal Medicine, Kwandong University College of Medicine, Myungji Hospital, Koyang, Korea.
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. sekyukim@yumc.yonsei.ac.kr
The Institute of Chest Diseases, Yonsei University College of Medicine, Seoul, Korea.
Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea.
Cancer Metastasis Research Center, Yonsei University College of Medicine, Seoul, Korea.
Abstract

BACKGROUND: The purpose of this study was to evaluate the usefulness of the pleural fluid carcinoembryonic antigen (CEA) and cytokeratin fragment 19 (CYFRA 21-1) tumor markers as complementary tools for the diagnosis of malignant pleural effusions. PATIENTS AND METHODS: The levels of pleural and serum CEA and CYFRA 21-1 were prospectively assayed in 222 patients with pleural effusions (150 benign effusions, 57 bronchogenic carcinomas and 15 metastatic carcinomas). RESULTS: The levels of pleural fluid CEA and CYFRA 21-1 in the malignant effusions were significantly higher than those in the benign effusions. With a specificity of 95%, the cut off values for the CEA and CYFRA 21-1 in pleural effusions were 5 and 89 ng/ml, respectively. The diagnostic sensitivities of the pleural fluid CEA and CYFRA 21-1 in malignant effusions were 72 and 54%, respectively, whereas using a combination of the two, the sensitivity increased to 87% (p<0.05). CONCLUSIONS : These findings suggest that a combination of the pleural fluid CEA and CYFRA 21-1 in pleural effusions can be useful in the diagnosis of malignant pleural effusions.

Copyright © 2019. Korean Association of Medical Journal Editors.